Skip to main content
. 2018 Feb 4;9(36):24237–24247. doi: 10.18632/oncotarget.24386

Figure 6.

Figure 6

Kaplan-Meier survival curves of progression-free survival in patients who received gefitinib, erlotinib, and afatinib (A) in brain metastasis and (B) in no brain metastasis.